Activated neutrophils have been implicated in the development of
ischemia/reperfusion (I/R)-induced
renal failure.
Cytokine-induced neutrophil chemoattractant-1 (CINC-1), a major factor in acute
inflammation, is responsible for the activation of neutrophils and for neutrophil chemotaxis to sites of injury.
Atrial natriuretic peptide (
ANP), a
hormone synthesized by the cardiac atria, was shown to possess anti-inflammatory potential due to its potency to inhibit the production of inflammatory mediators. We examined whether the human form of
ANP attenuates I/R-induced renal injury by reducing neutrophil activation in a rat model. Male Wistar rats weighing 200-240 g were observed for 24 h after reperfusion following 45-min renal
ischemia. Rats were intravenously administered alpha-human
ANP (
alpha-hANP, 0.2 microg/kg/min) beginning immediately after
ischemia and continuing for 2 h after reperfusion. CINC-1 and
myeloperoxidase (MPO) concentrations were measured to assess activation of the infiltrating neutrophil. Blood
urea nitrogen and serum
creatinine and urinary
N-acetyl beta-d-glucosaminidase (NAG) were measured as indicators of glomerular function and as a specific
indicator of proximal tubular function, respectively.
alpha-hANP significantly inhibited I/R-induced increases in renal CINC-1 and MPO concentrations.
alpha-hANP also reduced I/R-induced increases in the concentrations of blood
urea nitrogen and serum
creatinine, and improved histopathologic changes, including acute tubular
necrosis. These findings indicate that
alpha-hANP attenuates I/R-induced
acute renal injury, at least in part by reducing neutrophil activation, and may be useful in surgeries, associated with renal
ischemia, as well as in
renal transplantation.